Veru (NASDAQ:VERU) PT Raised to $31.00 at Brookline Capital Management

Veru (NASDAQ:VERUGet Rating) had its price target increased by stock analysts at Brookline Capital Management from $29.00 to $31.00 in a report issued on Wednesday, The Fly reports. The firm currently has a “buy” rating on the stock. Brookline Capital Management’s price objective suggests a potential upside of 116.33% from the company’s previous close.

A number of other equities analysts have also weighed in on VERU. TheStreet upgraded shares of Veru from a “d+” rating to a “c” rating in a research report on Friday, April 29th. Oppenheimer increased their target price on shares of Veru from $25.00 to $36.00 and gave the stock an “outperform” rating in a research report on Tuesday, April 12th. Jefferies Financial Group increased their price target on shares of Veru from $33.00 to $55.00 in a report on Friday, May 13th. Cantor Fitzgerald reissued an “overweight” rating on shares of Veru in a report on Friday, May 13th. Finally, Zacks Investment Research downgraded shares of Veru from a “buy” rating to a “hold” rating in a report on Thursday, April 21st. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $32.40.

NASDAQ:VERU traded down $1.27 on Wednesday, reaching $14.33. 465,774 shares of the company’s stock were exchanged, compared to its average volume of 22,628,762. The firm has a market cap of $1.15 billion, a price-to-earnings ratio of -41.97 and a beta of -0.58. Veru has a 52 week low of $4.34 and a 52 week high of $17.50. The stock has a fifty day simple moving average of $8.54 and a 200-day simple moving average of $7.14.

Veru (NASDAQ:VERUGet Rating) last issued its earnings results on Thursday, May 12th. The company reported ($0.18) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.02). Veru had a negative return on equity of 18.64% and a negative net margin of 45.56%. During the same quarter in the prior year, the business posted ($0.04) EPS. On average, equities analysts predict that Veru will post -0.52 EPS for the current fiscal year.

A number of institutional investors and hedge funds have recently made changes to their positions in VERU. PNC Financial Services Group Inc. raised its stake in Veru by 833.3% in the third quarter. PNC Financial Services Group Inc. now owns 5,600 shares of the company’s stock valued at $49,000 after purchasing an additional 5,000 shares in the last quarter. Ensign Peak Advisors Inc purchased a new stake in Veru in the fourth quarter valued at approximately $51,000. Josh Arnold Investment Consultant LLC purchased a new stake in Veru in the fourth quarter valued at approximately $59,000. Bridgefront Capital LLC purchased a new stake in Veru in the fourth quarter valued at approximately $63,000. Finally, XTX Topco Ltd raised its stake in Veru by 18.7% in the first quarter. XTX Topco Ltd now owns 14,426 shares of the company’s stock valued at $70,000 after purchasing an additional 2,270 shares in the last quarter. 29.11% of the stock is currently owned by institutional investors and hedge funds.

Veru Company Profile (Get Rating)

Veru Inc, an oncology biopharmaceutical company, focuses on developing medicines for the management of cancers. Its commercial products comprise FC2 female condom/internal condom for the dual protection against unintended pregnancy and the transmission of sexually transmitted infections for ministries of health, government health agencies, U.N.

Featured Stories

The Fly logo

Receive News & Ratings for Veru Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veru and related companies with MarketBeat.com's FREE daily email newsletter.